Details for New Drug Application (NDA): 020254
✉ Email this page to a colleague
NDA 020254 describes VOLTAREN-XR, which is a drug marketed by Novartis and is included in one NDA. Additional details are available on the VOLTAREN-XR profile page.
The generic ingredient in VOLTAREN-XR is diclofenac sodium. There are forty-seven drug master file entries for this compound. One hundred and twenty-eight suppliers are listed for this compound. Additional details are available on the diclofenac sodium profile page.
The generic ingredient in VOLTAREN-XR is diclofenac sodium. There are forty-seven drug master file entries for this compound. One hundred and twenty-eight suppliers are listed for this compound. Additional details are available on the diclofenac sodium profile page.
Summary for 020254
| Tradename: | VOLTAREN-XR |
| Applicant: | Novartis |
| Ingredient: | diclofenac sodium |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
| Approval Date: | Mar 8, 1996 | TE: | RLD: | Yes | |||||
Complete Access Available with Subscription
